Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharma Firms Stir OTC Market, FDA Hones Enforcement: Top Stories Of 2009

This article was originally published in The Tan Sheet

Executive Summary

Firms entering or expanding their presence in the OTC drug and nutritional product markets as part of pharmaceutical industry shuffling in 2009 attracted the attention of stakeholders already competing in those markets

You may also be interested in...



Sanofi Eyes Chattem As Key Building Block For Global OTC Growth

Sanofi-Aventis' $1.9 billion bid for OTC and personal care product firm Chattem offers the French firm a coveted toehold in the sizeable U.S. consumer health care market while also opening potential opportunities in emerging markets

Zegerid OTC Approved, Limited To Touting Dual-Ingredient Formula For Now

Merck's Schering-Plough Consumer HealthCare Products division will launchZegerid OTC in the first half of 2010 as the first dual-ingredient OTC proton pump inhibitor

Co-Packaging Enters Gray Area As Option For OTC/Supplement Combos

Experts disagree whether creative co-packaging of OTC drugs and dietary supplements is a legitimate alternative to problematic combination products or simply another regulatory quagmire

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103666

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel